
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



POSITIVE PROFIT ALERT

This announcement is made by WuXi Biologics (Cayman) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the six months ended June 30, 2022 (the "**Reporting Period**"), it is expected that revenue of the Company for the six months ended June 30, 2022 will increase between 61% to 63%; the profit of the Company and the profit attributable to equity shareholders of the Company for the six months ended June 30, 2022 will increase between 36% to 38% and 35% to 37%, respectively; and after adjusting for share-based compensation, foreign exchange gain & loss, investment fair value gain & loss, the non-IFRS adjusted net profit of the Company will increase between 58% to 60%, compared with those for the corresponding period of last year. Such increase was primarily attributable to, among other factors:

- (i) the successful execution of the Group's "Follow and Win the Molecule" strategies, keeping to gain more customers to achieve sustainable high growth;
- (ii) accelerated momentum for the Group's commercial manufacturing and late-stage businesses since the banner year of 2021, contributing to significant revenue growth;
- (iii) the Group's acceleration to undertake, promptly execute and generate revenue from existing and new projects to support and enable the Group's global clients in combatting against COVID;

- (iv) leading technology platform, best-in-industry timeline and excellent execution track record contributing to significantly higher revenue and market share of new non-COVID integrated projects;
- (v) enlarged spectrum of services offered to biologics industry, including the one-stop shop comprehensive drug product service, boosted the Group's revenue stream; and
- (vi) the full utilization of the existing capacities and resources and the implementation of operational efficiency improvement programs, coupled with successful executions of business continuity plan in Shanghai.

The Company's revenue growth exceeded the profitability growth in the Reporting Period primarily due to the following reasons: the first half of 2021 was an exceptional period with the record profitability and the Group took extraordinary efforts to undertake a large number of new integrated projects with very limited new headcount added. In the first half of 2022, the Group acquired the required talents, continued to build capacity and global footprint, further increased research and development ("**R&D**") spending to assure the long-term sustainable growth.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2022. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2022, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for the six months ended June 30, 2022, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for the six months ended June 30, 2022, which is expected to be published on August 17, 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board WuXi Biologics (Cayman) Inc. Dr. Ge Li *Chairman*

Hong Kong, July 19, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* For identification purpose only